Madrigal Pharmaceuticals upgraded by Raymond James
$MDGL
Biotechnology: Pharmaceutical Preparations
Health Care
Raymond James upgraded Madrigal Pharmaceuticals from Underperform to Mkt Perform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/28/2025 | $236.00 → $422.00 | Neutral → Buy | B. Riley Securities |
| 2/27/2025 | $400.00 → $405.00 | Buy | H.C. Wainwright |
| 6/28/2024 | Neutral | Cantor Fitzgerald | |
| 6/11/2024 | $382.00 | Outperform | Wolfe Research |
| 4/22/2024 | $150.00 | Underperform | BofA Securities |
| 3/15/2024 | $155.00 → $270.00 | Sell → Neutral | B. Riley Securities |
| 3/6/2024 | $382.00 | Buy | Citigroup |
| 2/26/2024 | $155.00 | Neutral → Sell | B. Riley Securities |
4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
4 - MADRIGAL PHARMACEUTICALS, INC. (0001157601) (Issuer)
Submission status for MADRIGAL PHARMACEUTICALS INC's drug REZDIFFRA (ORIG-1) with active ingredient RESMETIROM has changed to 'Approval' on 03/14/2024. Application Category: NDA, Application Number: 217785, Application Classification: Type 1 - New Molecular Entity